A carregar...
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favourable safety and tolerability profile, including the lack...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049051/ https://ncbi.nlm.nih.gov/pubmed/33269554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14277 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|